Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q2 2025 value amounting to $748000.0.

  • Day One Biopharmaceuticals' Cash from Financing Activities fell 4232.85% to $748000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 9871.36%. This contributed to the annual value of $203.3 million for FY2024, which is 2396.02% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Cash from Financing Activities of $748000.0 as of Q2 2025, which was down 4232.85% from $1.9 million recorded in Q4 2024.
  • Day One Biopharmaceuticals' 5-year Cash from Financing Activities high stood at $200.1 million for Q3 2024, and its period low was $48000.0 during Q1 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Cash from Financing Activities averaged around $44.5 million, with its median value being $1.6 million (2024).
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Cash from Financing Activities showed a top increase of 17389565.22% in 2024 and a maximum decrease of 9919.99% in 2024.
  • Day One Biopharmaceuticals' Cash from Financing Activities (Quarter) stood at $1.9 million in 2022, then tumbled by 68.87% to $597000.0 in 2023, then surged by 210.05% to $1.9 million in 2024, then tumbled by 59.59% to $748000.0 in 2025.
  • Its Cash from Financing Activities was $748000.0 in Q2 2025, compared to $1.9 million in Q4 2024 and $200.1 million in Q3 2024.